Manufacture Biosimilars

Generics Deliver Savings

Generic drugs are cheaper than branded medicines, but how much do they save payers each year?

James Strachan | 11/21/2016

The latest Generic Drug Savings and Access Report, commissioned by the Generic Pharmaceutical Association, found that generic medicines save the US around $230 billion each year (1). The findings build upon those of a report published last year, which found that generics save the European Union around €100 billion ($112 billion) per year (2). Check out our infographic for more of the findings.

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Manufacture Biosimilars

GPhA, “2016 generic drug savings & access in the United States Report”, (2016). Available at: bit.ly/2f7CcqT. Accessed November 4, 2016.
IMS Institute for Healthcare Informatics, “The role of generic medicines in sustaining healthcare systems: a European perspective”, (2015). Available at: bit.ly/2eumuYz. Accessed November 4, 2016.

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at.

From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.